
Surmodics SRDX
Quarterly report 2025-Q2
added 08-08-2025
Surmodics P/E Ratio 2011-2026 | SRDX
Annual P/E Ratio Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -48 | -313 | -18.6 | 146 | 628 | 82.8 | -188 | 98.4 | 32.6 | 23.3 | 24.5 | 23.1 | 32.2 | -14.9 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 628 | -313 | 36.3 |
P/E Ratio of other stocks in the Diagnostics research industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-10.3 | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
-0.479 | - | -17.87 % | $ 25.9 M | ||
|
Bioventus
BVS
|
26.7 | $ 8.99 | 1.35 % | $ 599 M | ||
|
Brainsway Ltd.
BWAY
|
-37.1 | $ 13.73 | 0.59 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
38.9 | $ 25.9 | 0.27 % | $ 719 M | ||
|
Aspira Women's Health
AWH
|
-1.67 | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
30.5 | $ 67.32 | 1.48 % | $ 26.3 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-233 | - | - | $ 562 M | ||
|
Guardant Health
GH
|
-32.3 | $ 88.75 | 1.8 % | $ 11.1 B | ||
|
Charles River Laboratories International
CRL
|
-53.3 | $ 153.71 | 1.14 % | $ 7.62 B | ||
|
CareDx, Inc
CDNA
|
-46.5 | $ 17.6 | 1.62 % | $ 938 M | ||
|
Accelerate Diagnostics
AXDX
|
-2.76 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-93.8 | $ 103.94 | 0.09 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
0.485 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-9.08 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-1.29 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-3.07 | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
-10.9 | $ 15.43 | 3.21 % | $ 467 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
39.9 | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
-2.14 | $ 16.59 | -4.05 % | $ 2.15 B | ||
|
ICON Public Limited Company
ICLR
|
21 | $ 100.49 | 2.95 % | $ 8.29 B | ||
|
Anixa Biosciences
ANIX
|
-0.00947 | $ 2.89 | 1.76 % | $ 93.8 K | ||
|
IQVIA Holdings
IQV
|
20.8 | $ 168.43 | 2.15 % | $ 29 B | ||
|
Danaher Corporation
DHR
|
41.4 | $ 195.21 | 2.0 % | $ 139 B | ||
|
Biocept
BIOC
|
-0.185 | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
-42.4 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-0.138 | - | -20.0 % | $ 1.06 M | ||
|
Pacific Biosciences of California
PACB
|
-0.911 | $ 1.38 | 1.47 % | $ 414 M | ||
|
Illumina
ILMN
|
-13.4 | $ 120.84 | 1.31 % | $ 19.2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
23.5 | $ 198.61 | -0.17 % | $ 22 B | ||
|
QIAGEN N.V.
QGEN
|
102 | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
34.7 | $ 112.75 | 0.82 % | $ 34.3 B | ||
|
BioNano Genomics
BNGO
|
-0.0317 | $ 1.13 | 1.8 % | $ 1.44 M | ||
|
DarioHealth Corp.
DRIO
|
-0.73 | $ 8.75 | 3.92 % | $ 248 M | ||
|
NeoGenomics
NEO
|
-13.7 | $ 8.27 | 0.36 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
-0.933 | $ 9.27 | 1.76 % | $ 2.01 B | ||
|
Lantheus Holdings
LNTH
|
21.9 | $ 80.45 | 2.48 % | $ 5.43 B | ||
|
Chembio Diagnostics
CEMI
|
-0.54 | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-0.172 | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
-0.988 | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
28.7 | $ 455.15 | 0.33 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
-0.0769 | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
32.7 | $ 1 206.72 | 0.63 % | $ 24.9 B | ||
|
Celcuity
CELC
|
-3.57 | $ 114.11 | -0.69 % | $ 4.5 B | ||
|
DermTech
DMTK
|
-0.421 | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
27.2 | $ 17.73 | 1.9 % | $ 397 M | ||
|
Twist Bioscience Corporation
TWST
|
-20.1 | $ 47.28 | 5.04 % | $ 2.83 B | ||
|
Invitae Corporation
NVTA
|
-5.12 | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
-0.00221 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
-9.69 | $ 198.38 | 0.35 % | $ 19.5 B |